New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 5, 2018 - Horizon Pharma announced the FDA approval of Procysbi (cysteamine bitartrate), for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Download PDF
Return to publications
